×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:FSTX

F-star Therapeutics News Headlines

$6.39
+0.03 (+0.47%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$6.07
$6.45
50-Day Range
$2.18
$6.36
52-Week Range
$2.07
$9.30
Volume
1.22 million shs
Average Volume
207,898 shs
Market Capitalization
$137.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Get F-star Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FSTX and its competitors with MarketBeat's FREE daily newsletter.

FSTX Media Mentions By Week

FSTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FSTX
News Sentiment

-0.25

0.38

Average
Medical
News Sentiment

FSTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FSTX Articles
This Week

12

1

FSTX Articles
Average Week



FSTX Stock News Headlines Today

SourceHeadline
marketbeat.com logoF-star Therapeutics (NASDAQ:FSTX) Stock Rating Lowered by SVB Leerink
marketbeat.com - June 23 at 4:32 PM
marketbeat.com logoF-star Therapeutics, Inc. (NASDAQ:FSTX) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - June 23 at 4:13 PM
MarketBeat logoF-star Therapeutics (NASDAQ:FSTX) Downgraded to "Neutral" at LADENBURG THALM/SH SH
americanbankingnews.com - June 24 at 5:46 AM
benzinga.com logoShareholder Alert: Ademi LLP investigates whether F-star Therapeutics, Inc. has obtained a Fair Price in its transaction with invoX
benzinga.com - June 23 at 6:26 PM
apnews.com logoFSTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders
apnews.com - June 23 at 6:26 PM
marketwatch.com logoF-star Therapeutics Shares Soar on Buyout Deal >FSTX
marketwatch.com - June 23 at 6:26 PM
finance.yahoo.com logoinvoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
finance.yahoo.com - June 23 at 7:48 AM
finance.yahoo.com logoF-star Therapeutics, Inc. (NASDAQ:FSTX) Just Reported And Analysts Have Been Cutting Their Estimates
finance.yahoo.com - May 14 at 3:29 PM
barrons.com logoF-star Therapeutics Inc.
barrons.com - May 13 at 8:50 PM
nasdaq.com logoFstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
nasdaq.com - May 10 at 12:46 PM
finance.yahoo.com logoF-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 12:46 PM
finance.yahoo.com logoF-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
finance.yahoo.com - May 2 at 10:24 AM
finanznachrichten.de logoF-star Therapeutics, Inc.: F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
finanznachrichten.de - April 8 at 10:35 AM
finance.yahoo.com logoF-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
finance.yahoo.com - April 8 at 10:35 AM
finance.yahoo.com logoStrong week for F-star Therapeutics (NASDAQ:FSTX) shareholders doesn't alleviate pain of one-year loss
finance.yahoo.com - March 21 at 8:15 PM
benzinga.com logoHC Wainwright & Co. Initiates Coverage On F-star Therapeutics with Buy Rating, Announces Price Target of $35
benzinga.com - March 18 at 12:38 AM
seekingalpha.com logoF-star Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation
seekingalpha.com - March 14 at 10:55 AM
finanznachrichten.de logoF-star Therapeutics, Inc.: F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
finanznachrichten.de - March 14 at 10:18 AM
finance.yahoo.com logoF-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 10:18 AM
finance.yahoo.com logoF-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 10 at 11:07 AM
finance.yahoo.com logoF-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
finance.yahoo.com - March 2 at 8:13 AM
finance.yahoo.com logoF-star Therapeutics Appoints James Sandy as Chief Development Officer
finance.yahoo.com - March 1 at 10:13 PM
seekingalpha.com logoF-star Therapeutics gets US patent for antibody FS118
seekingalpha.com - January 22 at 6:31 PM
finanznachrichten.de logoF-star Therapeutics, Inc.: F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
finanznachrichten.de - January 20 at 10:48 AM
finance.yahoo.com logoF-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
finance.yahoo.com - January 20 at 10:48 AM
nasdaq.com logoF-star Therapeutics Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - January 13 at 2:50 AM
finance.yahoo.com logoF-star Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - January 7 at 9:17 AM
markets.businessinsider.com logoF-star Therapeutics : Merck KGaA Exercises Fourth Licensing Option In Immuno-Oncology Collaboration
markets.businessinsider.com - January 5 at 1:38 PM
finance.yahoo.com logoF-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
finance.yahoo.com - January 5 at 8:38 AM
msn.com logoPeering Into F-star Therapeutics Recent Short Interest
msn.com - December 31 at 2:16 PM
finance.yahoo.com logoF-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
finance.yahoo.com - December 7 at 11:41 AM
finance.yahoo.com logoF-star Therapeutics to Host Virtual R&D Day on December 6, 2021
finance.yahoo.com - November 29 at 12:14 PM
nasdaq.com logoF-star Therapeutics (FSTX) Sees Hammer Chart Pattern: Time to Buy?
nasdaq.com - November 15 at 8:21 AM
markets.businessinsider.com logoF-star Therapeutics, Inc. : F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
markets.businessinsider.com - November 13 at 5:02 AM
finance.yahoo.com logoF-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
finance.yahoo.com - November 12 at 12:33 PM
finance.yahoo.com logoAerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors
finance.yahoo.com - November 11 at 8:43 AM
finance.yahoo.com logoF-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 10 at 9:38 AM
finance.yahoo.com logoF-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
finance.yahoo.com - November 1 at 6:45 PM
finance.yahoo.com logoF-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
finance.yahoo.com - October 20 at 10:44 AM
finance.yahoo.com logoF-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021
finance.yahoo.com - September 16 at 9:56 AM
finance.yahoo.com logoF-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 9 at 9:35 AM
finanznachrichten.de logoF-star Therapeutics, Inc.: F-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
finanznachrichten.de - August 12 at 5:56 PM
finance.yahoo.com logoF-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - August 12 at 5:56 PM
finanznachrichten.de logoF-star Therapeutics, Inc.: F-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
finanznachrichten.de - August 10 at 12:56 PM
nasdaq.com logoWhy F-star Therapeutics (FSTX) Might Surprise This Earnings Season
nasdaq.com - August 10 at 12:56 PM
finance.yahoo.com logoF-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285
finance.yahoo.com - August 10 at 12:56 PM
finance.yahoo.com logoF-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA
finance.yahoo.com - August 4 at 12:38 PM
finance.yahoo.com logoF-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021
finance.yahoo.com - August 2 at 1:30 PM
finance.yahoo.com logoF-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
finance.yahoo.com - July 26 at 12:12 PM
nasdaq.com logoTop Stocks To Watch This Week? 4 Biotech Stocks To Know
nasdaq.com - July 15 at 11:41 PM
msn.com logoWhy F-Star Therapeutics Shares Are Trading Higher Today
msn.com - July 8 at 3:00 PM
ca.finance.yahoo.com logoIONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
ca.finance.yahoo.com - June 29 at 10:16 AM
Get F-star Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FSTX and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:FSTX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.